Efficacy and Safety of Direct Oral Anticoagulants in Patients With Atrial Fibrillation Combined With Hypertension: A Multicenter, Retrospective Cohort Study
暂无分享,去创建一个
M. Zhang | Nianxu Huang | Xia Chen | Wang Zhang | Hengfen Dai | P. Gu | Xiaohong Huang | Qiaowei Zheng | Yuxin Liu | Xiu-Qin Liu | Zhu Zhu | Jin-hua Zhang | Tingting Wu | M. Lv | Wenlin Xu | X. Du | Chengfu Guan | Ruijuan Li | Xiangsheng Lin
[1] D. Conen,et al. Novel bleeding risk score for patients with atrial fibrillation on oral anticoagulants, including direct oral anticoagulants , 2021, Journal of thrombosis and haemostasis : JTH.
[2] F. Violi,et al. Long-Term Risk of Major Adverse Cardiac Events in Atrial Fibrillation Patients on Direct Oral Anticoagulants. , 2020, Mayo Clinic proceedings.
[3] G. Barnes,et al. Stroke and thromboembolism prevention in atrial fibrillation , 2019, Heart.
[4] G. Lip,et al. Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation. , 2019, Chest.
[5] M. Riva,et al. From Healthy Aging to Frailty: In Search of the Underlying Mechanisms. , 2019, Current medicinal chemistry.
[6] D. Liebeskind,et al. The importance of comorbidities in ischemic stroke: Impact of hypertension on the cerebral circulation , 2018, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[7] S. Willmann,et al. Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations , 2018, CPT: pharmacometrics & systems pharmacology.
[8] R. Sah,et al. Role of diabetes and insulin use in the risk of stroke and acute myocardial infarction in patients with atrial fibrillation: A Medicare analysis. , 2018, American heart journal.
[9] Ulrich Schotten,et al. 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. , 2017, Revista espanola de cardiologia.
[10] P. Kirchhof,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[11] J. Rassen,et al. Optimal matching ratios in drug safety surveillance. , 2014, Epidemiology.
[12] Stanley Nattel,et al. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. , 2014, Circulation research.
[13] C. Murray,et al. Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study , 2014, Circulation.
[14] S. Yusuf,et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). , 2014, Journal of the American College of Cardiology.
[15] P. Austin. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments , 2013, Statistics in medicine.
[16] R. Giugliano,et al. Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 79 808 patients , 2013, Heart.
[17] Mårten Rosenqvist,et al. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. , 2012, European heart journal.
[18] G. Albers,et al. Dabigatran challenges warfarin's superiority for stroke prevention in atrial fibrillation. , 2010, Stroke.
[19] D. S. Houston,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[20] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[21] G. Lip,et al. Effect of hypertension on anticoagulated patients with atrial fibrillation. , 2007, European heart journal.
[22] S. Sacco,et al. Contribution of Atrial Fibrillation to Incidence and Outcome of Ischemic Stroke: Results From a Population-Based Study , 2005, Stroke.
[23] S. Schulman,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.
[24] V. Santinelli,et al. Prevention of Atrial Fibrillation: , 2004, Journal of cardiovascular electrophysiology.
[25] D. Levy,et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. , 1994, JAMA.
[26] M. Glanz,et al. The Sharer , 2000, Annals of Internal Medicine.